Posts

de-escalation and escalation treatment of early breast cancer—Interview with Giuseppe Curigliano at SGBCC 2023

surgery of the primary for stage IV disease—Interview with William Gradishar at SGBCC 2023

Do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)

An interview with Professor Masatoshi Kudo - Interpreting Final analysis of RATIONALE-301

ESMO 2022丨Interview with Professor Andrés Cervantes: See you in Madrid

Prof. Hope S. Rugo: Interpretation of Overall Survival Outcomes of TROPiCS-02 Study

Prof. Laurence Buisseret: SYNERGY Study - Exploration of double immunity combined with chemotherapy in patients with mTNBC

Prof. Matthew Goetz: ELAINE 1 Study - Treatment Options for Patients with ESR1 Mutated Breast Cancer after CDK4/6i Progression